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The prompt achievement of (vaccine-derived) herd immunity worldwide should be the core
aim of all COVID-19 vaccination programmes, as it would thereby minimize viral
transmission both between and within countries [1, 2]. Failure to address underlying
structural and systemic inequalities in the acquisition and delivery of vaccinations is a
fundamental ethical and moral concern. Additionally, there is a strategic imperative with
pragmatic consequences in ensuring other vital goals of comprehensive global vaccination.
These include: supporting sustainable economic development; allowing international travel/
movement; and restoring adequate, accessible health and social care systems for all
populations worldwide.
No region/nation will truly be free of the pandemic until all nations are free of it. Until an
international consensus has been reached and a coordinated operational strategy has been
adopted, the virus will find new vulnerable populations and continue to spread [3]. It will
neither respect international boundaries, nor be limited/eradicated by sporadic vaccination
coverage across populations and countries. It will continue to replicate and mutate to new,
unpredictable forms, which potentially limit the effectiveness of current and future vaccines, and
further threaten global health security and economic prosperity. Consequently, there will persist a
need for restrictions on international travel, variably and inadequately implemented by individual
countries.
ASPHER is deeply concerned about chaotic differences in vaccination policies between and within
countries which threaten our collective ability to control and suppress the virus worldwide [4]. Given
the potential for further virus mutations, some of which may be vaccine-resistant, the need for a
coordinated global approach to vaccination through an equity lens has never been more evident. We
need to overcome the ugly face of ‘vaccine nationalism’ and replace it with ‘vaccine internationalism’
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[5] if we are to address the challenges impeding global access to
COVID-19 vaccines (production, affordability, allocation, and
deployment) [6].
ASPHER calls upon theWHO to lead efforts in securing global
international collaboration and capacity (in immunology,
virology, public health, and vaccinology) to anticipate potential
antigenic drift/shift in the severe acute respiratory syndrome
coronavirus 2 (SARS-COV-2) virus. It is crucial for the WHO
to not only bolster its efforts to maintain and develop
comprehensive vaccine responses to the virus, but also adapt
them to combat potential new strains.
ASPHER calls upon national governments to commit to
international vaccine leadership through the WHO, supported
by other key international agencies and integrated with the
COVAX GAVI initiative. National governments must adopt
an international consensus with a clear public health strategy
and measurable targets for reducing the virus spread. Such a
strategy requires recognition of the need for appropriate
vaccine deployment, in accordance with local health system
contexts and is not merely about obtaining funding to support
poorer countries with vaccine access [7]. ASPHER further calls
on national governments to contribute to a coordinated
international effort to ensure vaccine deployment
programmes are comprehensive and fit for purpose, with
considerations made regarding the circumstances within
countries in which they are administered. Additionally, we
call on national governments to strengthen issues around
anticipating new variants and decreasing effectiveness of
vaccines, proactively planning for if/when vaccines stop
working to prevent mild/moderate disease as well as
considering how countries are reimbursed for vaccines
purchased which may be less effective. Finally, it is essential
that national governments evaluate their need to access global
vaccine stockpiles, bearing in mind the context of global
equity.
Global surveillance and disease epidemiology, rapid reporting of
vaccine delivery and uptake with planned seroprevalence studies,
and support for alerting and mobilizing outbreak control for
emergent diseases within the rapid reporting dashboard are
crucial components of a coordinated global approach.
Therefore, ASPHER calls upon the WHO and national public
health agencies to develop an international nomenclature for
current and future virus mutations as well as urgently revise
and agree on global evaluation frameworks for COVID-19
vaccines, building upon historical and recent pandemic-related
approaches to communicable disease control, elimination, and
eradication. We further call for the reporting of funding levels
backed with COVAX pledges from countries and timely delivery of
vaccines as well as the facilitation of post-marketing surveillance,
including that of pharmaceutical companies.
ASPHER also calls upon civil society organisations (CSOs)
and schools of public health to support the WHO and national
governments in catalyzing efforts to combat the spread of
disinformation and misinformation. CSOs and schools of
public health must not only continue to convey factual,
evidence-based information, but also identify and share best
practices and expertize with policymakers.
ASPHER strongly believes the creation of a range of vaccines to
combat SARS-COV-2 is a major scientific achievement brought about
through truly international efforts. We reinforce our stance on the need
for transparent and evidence-based decisionmaking in policy, particularly
with respect to vaccination approaches [8]. The willingness of scientists to
collaboratemust nowbematched bypoliticians fromall nations.Without
coordinated global capacity and collaboration to anticipate new virus
strains and new vaccine modifications, wemay be faced with a perpetual
COVIDpandemic. As such, the costly ‘vaccine nationalism’we have seen
thus far must not persist [9].
Politicians of all nations must commit to a global strategy for
the control and eventual elimination of the SARS-COV-2 virus.
There must be a genuine commitment to ensuring equitable
access to vaccines both between and within countries. This is
more than just a fundamental question of fairness and the right
of all global citizens to health. The virus will not be eliminated
anywhere, if it is not eliminated everywhere. Restoring the
pursuit of health and better socioeconomic futures for all
requires global commitment to the largest vaccination
program to date. For this to succeed, nations will need to
pool their resources and sovereignty, and put their weight
behind the WHO’s leadership.
Recent disputes between the EU and the United Kingdom
on vaccine distribution [10] drastically undermine effective
vaccine rollout globally, doing more harm than good. Political
leaders have set high expectations among their citizens to
ensure rapid vaccine rollouts; however, limitations in
technical production are inherent to all vaccine production
efforts. While we have seen extraordinary success so far and so
quickly, it is important to bear in mind that disinformation
and misinformation will persist, and there are both
commercial and political factors at play which can
exacerbate existing health inequities [1]. Vaccine
internationalism requires measured calm heads, diplomacy,
and generous visionary leadership. Our aim above everything
else as a global community needs to be defeating the virus first.
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